SCHEMBL21282156

SCHEMBL21282156

COc1ccc2nc(-c3noc(-c4cc(Cl)nc(OC)c4)n3)ccc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ S1PR1 P21453 4/20 0.44
▸ RAB9A P51151 9/20 0.43
▸ NPC1 O15118 8/20 0.43
▸ SMN1; SMN2 Q16637 7/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ TSHR P16473 2/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.43
▸ SMO Q99835 1/20 0.42
▸ MAPT P10636 5/20 0.42
▸ PKM P14618 3/20 0.41
▸ GRM5 P41594 1/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ HSP90AA1 P07900 1/20 0.40
▸ HPGD P15428 3/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ TP53 P04637 1/20 0.40
▸ NFKB1 P19838 1/20 0.40
▸ NFKB2 Q00653 1/20 0.40
▸ RELA Q04206 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21282219 0.92 RAB9A (0.48) S1PR1RAB9ANPC1SMN1; SMN2MEN1
SCHEMBL21273251 0.83 S1PR1 (0.53) S1PR1RAB9ANPC1SMN1; SMN2MEN1
SCHEMBL21282194 0.81 NPC1 (0.56) S1PR1RAB9ANPC1SMN1; SMN2MEN1
SCHEMBL21282179 0.80 NPC1 (0.64) RAB9ANPC1SMN1; SMN2MEN1KMT2A
SCHEMBL21282172 0.80 NPC1 (0.61) S1PR1RAB9ANPC1SMN1; SMN2TSHR
SCHEMBL21282193 0.78 KDM4E (0.60) RAB9ANPC1SMN1; SMN2TSHRMAPT
SCHEMBL21282157 0.77 S1PR1 (0.66) S1PR1RAB9ANPC1SMN1; SMN2MEN1
SCHEMBL21273248 0.76 RAB9A (0.65) S1PR1RAB9ANPC1SMN1; SMN2TSHR
SCHEMBL21282216 0.76 NPC1 (0.54) S1PR1RAB9ANPC1SMN1; SMN2MEN1
SCHEMBL21282220 0.75 POLB (0.46) S1PR1RAB9ANPC1SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190256492-A1 ALPHA-SYNUCLEIN LIGANDS WASHINGTON UNIVERSITY (US) 2019-08-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190256492-A1 ALPHA-SYNUCLEIN LIGANDS SNCA, PARK7, LRRK2 S1PR1 1435/4885RAB9A 152/4885NPC1 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback